PhD Scientific Days 2025

Pathological and Oncological Sciences I.

Investigation of the immunoregulatory effects of vesicles derived from genetically modified embryonic stem cells

Előadó neve

Ms. Nagy Boglárka

Neptun code

MBAKEN

Előadó munkahelye

Genetics, Cell-, and Immunbiology Institute

Előadó telefonszáma

+36 30 203 3005

Előadó e-mail címe

nagyboglarka23@gmail.com

Az előadás címe

Investigation of the immunoregulatory effects of vesicles derived from genetically modified embryonic stem cells

Szerző(k) neve és munkahelye

Boglárka Nagy¹, Luigi Menna¹, Kristóf Csont¹, Nóra Fekete¹, Xabier Osteikoetxea¹, Adrienn Szabó¹, Angéla Takács¹, Edit Buzás¹, Hargita Hegyesi¹

1: Genetics, Cell-, and Immunbiology Institute

Bemutatás módja

Szóbeli

Szekció

Pathological and Oncological Sciences I.

Language of the presentation

English

Preferred session

Pathological and Oncological Sciences

Összefoglaló szövege

Investigation of the Immunoregulatory Effects of Vesicles Derived from Genetically Modified Embryonic Stem Cells

Introduction:
Extracellular vesicles (EVs) from embryonic stem cells are emerging as promising therapeutic tools due to their ability to deliver bioactive molecules—such as proteins, lipids, and RNAs—targetedly. They promote regeneration, reduce inflammation, and present fewer ethical and immunological concerns than direct stem cell therapies.
Aims:
This study examined how a mouse embryonic stem cell line, stably transfected with eight genes, and its derived EVs affect peripheral mononuclear cell populations. The hypothesis was that these modified cells and their EVs could modulate immune responses and serve as potential therapeutic agents.
Methods:
The NT2 cell line expresses seven immunoregulatory proteins and a thymidine kinase gene for selective elimination. EVs were isolated from conditioned medium via differential centrifugation. Vesicle size and concentration were analyzed by nanoparticle tracking, and surface markers identified by flow cytometry. Immunomodulatory effects were assessed in vitro and in vivo by measuring CD4+, CD8+ T cells, B cells, and monocytes.
Result:
NT2-derived EVs expressed Annexin V, CD81, and the immunoregulatory molecules PDL-1, CD47, and CD200—absent in control EVs. NT2 cells, both in direct and indirect co-culture, reduced activated T cell numbers. In vivo, teratomas from NT2 cells significantly decreased CD4+, CD8+ T cells, and monocytes in peripheral blood.
Conclusion:
EVs from genetically modified embryonic stem cells carry key immunoregulatory molecules and reduce immune cell counts, indicating their potential as future tools in immunomodulatory therapy.
Funding: TKP2021-EGA-23. This study was also supported by the grants RRF-2.3.121-2022-00003 (National Cardiovascular Laboratory Program) and 2019-2.1.7-ERA-NET-2021-00015. The project has received funding from the EU’s Horizon 2020 Research and Innovation Programme under grant agreement No. 739593 and the NKFIH Advanced grant 150767.


E-mail: nagyboglarka23@gmail.com
Name of the University: Semmelweis University
Name of the Supervisor: dr. Hegyesi Hargita
For me it is preferred to be presented as an oral presentation (in English).

University

Semmelweis University

Supervisor

dr. Hegyesi Hargita

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

phd.section.field

before finishing undergraduate studies (TDK, MD-PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

jóváhagyta

Előadó

9130

Start

15:00

End

15:15